Evaluating or acquiring a pharmaceutical asset demands more than financial analysis. The true value of a program or platform depends on its science, quality systems, manufacturing readiness, and regulatory trajectory. Overlooked CMC or compliance issues can delay timelines, raise costs, or diminish long term value.
Pharmatech Associates, a USP company, delivers comprehensive due diligence and in licensing support across drug substance, drug product, and corporate transactions. We help investors, biopharma companies, and CDMOs validate opportunities, uncover risks, and chart integration pathways with confidence
Our consultants bring decades of technical, regulatory, and quality expertise to ensure opportunities are evaluated accurately. We dig into the details that determine long term success, from regulatory filings to facility compliance.
Key areas we assess:
Pharmatech supports both acquirers and licensors in making informed, confident decisions. We validate data packages, identify gaps, and provide clear recommendations that impact valuation, deal structure, and long term performance.
Our support includes:
Our due diligence and in licensing services provide a clear, data driven picture of technical, regulatory, and quality risks. We deliver insights that safeguard investments and position programs for success.
We help you:
Whether you are evaluating a single asset, acquiring a platform company, or negotiating an in licensing deal, Pharmatech Associates provides the technical and regulatory expertise to reduce risk and maximize opportunity.
Our unique approach can help your company navigate the complexities of launching a drug, biologic or medical device into multiple markets. The first step? Connecting. Simply fill out our form and a representative will follow-up shortly.
1.877.787.0177
510.732.0177
22320 Foothill Blvd. Suite 330, Hayward CA 94541
